Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer.
Kawai T, Taguchi S, Nozaki K, Kimura N, Oshina T, Iwaki T, Matsui H, Niimi A, Kamei J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Kaneko T, Sawayanagi S, Nakayama H, Minamimoto R, Yamashita H, Miyazaki H, Fujimura T, Nakagawa T, Kume H.
Kawai T, et al. Among authors: sawayanagi s.
Prostate Int. 2023 Dec;11(4):239-246. doi: 10.1016/j.prnil.2023.10.002. Epub 2023 Oct 21.
Prostate Int. 2023.
PMID: 38196558
Free PMC article.